Embryogenesis and gene targeting of coagulation factors in mice

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 2, 2003, Pages 169-181

  Sood, Rashmi ^a   Weiler, Hartmut ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Embryonic development; Feto maternal interface; Gene targeting; Mice; Protease activated receptors; Thrombomodulin protein C pathway; Trophoblast

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; PROTEIN C; THROMBOMODULIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; FATTY ACID BINDING PROTEIN; HEPARIN; PLASMINOGEN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL MODEL; BLOOD CLOTTING DISORDER; BLOOD VESSEL FUNCTION; DISEASE ASSOCIATION; EMBRYO DEVELOPMENT; FETOPLACENTAL UNIT; FETUS WASTAGE; GENE TARGETING; GENETIC DISORDER; MOUSE; NONHUMAN; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOPHILIA; TROPHOBLAST; VASCULAR DISEASE; VASCULAR PATENCY; ANTICOAGULATION; DRUG INHIBITION; HEMOSTASIS; HUMAN; MOTHER FETUS RELATIONSHIP;

EID: 0038656542     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)00092-0     Document Type: Review

References (59)

1. Aasrum M & Prydz H. Gene targeting of tissue factor, factor X, and factor VII in mice: their involvement in embryonic development. Biochemistry (Moscow) 2002; 67: 25-32.
2. Bugge TH, Xiao Q, Kombrinck KW et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell- associated initiator of blood coagulation. Proceedings of the National Academy of Sciences of the USA 1996; 93: 6258-6263.
3. Carmeliet P, Mackman N, Moons L et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-75.
4. Toomey JR, Kratzer KE, Lasky NM et al. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996; 88: 1583-1587.
5. Sun WY, Witte DP, Degen JL et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proceedings of the National Academy of Sciences of the USA 1998; 95: 7597-7602.
6. Xue J, Wu Q, Westfield LA et al. Incomplete embryonic lethality and fatal neonatal haemorrhage caused by prothrombin deficiency in mice. Proceedings of the National Academy of Sciences of the USA 1998; 95: 7603-7607.
7. Cui J, O'Shea KS, Purkayastha A et al. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996; 384: 66-68.
8. Dewerchin M, Liang Z, Moons L et al. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thrombosis & Haemostasis 2000; 83: 185-190.
9. Suh TT, Holmback K, Jensen NJ et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes & Development 1995; 9: 2020-2033.
10. Degen JL, Drew AF, Palumbo JS et al. Genetic manipulation of fibrinogen and fibrinolysis in mice. Annals of the New York Academy of Sciences 2001; 936: 276-290.
11. Carmeliet P. Biomedicine. Clotting factors build blood vessels. Science 2001; 293: 1602-1604.
12. Franchi F, Biguzzi E, Cetin I et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. British Journal of Haematology 2001; 114: 641-646.
13. Gris JC, Quere I, Monpeyroux F et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent - the nimes obstetricians and haematologists study 5 (NOHA5). Thrombosis & Haemostasis 1999; 81: 891-899.
14. Sanson BJ, Friederich PW, Simioni P et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thrombosis & Haemostasis 1996; 75: 387-388.
15. Eldor A. Thrombophilia, thrombosis and pregnancy. Thrombosis & Haemostasis 2001; 86: 104-111.
16. Brenner B, Sarig G, Weiner Z et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thrombosis & Haemostasis 1999; 82: 6-9.
17. Grandone E, Margaglione M, Colaizzo D et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thrombosis & Haemostasis 1997; 77: 822-824.
18. Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. New England Journal of Medicine 1999; 340: 9-13.
19. Pihusch R, Buchholz T, Lohse P et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. American Journal of Reproductive Immunology 2001; 46: 124-131.
20. Arkel YS & Ku DH. Thrombophilia and pregnancy: review of the literature and some original data. Clinical and Applied Thrombosis/Hemostasis 2001; 7: 259-268.
21. Huang ZF, Higuchi D, Lasky N & Broze Jr. GJ. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-951.
22. Huang ZF & Broze Jr. G. Consequences of tissue factor pathway inhibitor gene-disruption in mice. Thrombosis & Haemostasis 1997; 78: 699-704.
23. Broze Jr. GJ. Tissue factor pathway inhibitor gene disruption. Blood Coagulation & Fibrinolysis 1998; 9(supplement 1): S89-S92.
24. Chan JC, Carmeliet P, Moons L et al. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. Journal of Clinical Investigation 1999; 103: 475-482.
25. Chan JC. Gene targeting in haemostasis. tissue factor pathway inhibitor. Frontiers in Bioscience 2001; 6: D216-D221.
26. Esmon NL, Owen WG & Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. Journal of Biological Chemistry 1982; 257: 859-864.
27. Taylor Jr. FB, Peer GT, Lockhart MS et al. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97: 1685-1688.
28. Bajzar L, Kalafatis M, Simioni P & Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. Journal of Biological Chemistry 1996; 271: 22 949-22 952.
29. Taylor Jr. FB & Lockhart MS. A new function for activated protein C: activated protein C prevents inhibition of plasminogen activators by releasate from mononuclear leukocytes-platelet suspensions stimulated by phorbol diester. Thrombosis Research 1985; 37: 155-164.
30. D'Angelo A, Lockhart MS, D'Angelo SV & Taylor Jr. FB. Protein S is a cofactor for activated protein C neutralization of an inhibitor of plasminogen activation released from platelets. Blood 1987; 69: 231-237.
31. Esmon CT. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. Journal of Autoimmunity 2000; 15: 113-116.
32. Esmon CT. Role of coagulation inhibitors in inflammation. Thrombosis & Haemostasis 2001; 86: 51-56.
33. Riewald M, Petrovan RJ, Donner A et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
34. Jalbert LR, Rosen ED, Moons L et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. Journal of Clinical Investigation 1998; 102: 1481-1488.
35. Chan JC, Ganopolsky JG, Cornelissen I et al. The characterization of mice with a targeted combined deficiency of protein c and factor XI. American Journal of Pathology 2001; 158: 469-479.
36. Healy AM, Rayburn HB, Rosenberg RD & Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proceedings of the National Academy of Sciences of the USA 1995; 92: 850-854.
37. Rosenberg RD. Thrombomodulin gene disruption and mutation in mice. Thrombosis & Haemostasis 1997; 78: 705-709.
38. Weiler-Guettler H, Aird WC, Rayburn H et al. Developmentally regulated gene expression of thrombomodulin in postimplantation mouse embryos. Development 1996; 122: 2271-2281.
39. Weiler-Guettler H, Christie PD, Beeler DL et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. Journal of Clinical Investigation 1998; 101: 1983-1991.
40. Isermann B, Hendrickson SB, Zogg M et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. Journal of Clinical Investigation 2001; 108: 537-546.
41. Isermann B, Hendrickson SB, Hutley K et al. Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 2001; 128: 827-838.
42. Gu JM, Crawley JT, Ferrell G et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. Journal of Biological Chemistry 2002;. (in press).
43. Crawley JT, Gu JM, Ferrell G & Esmon CT. Distribution of endothelial cell protein C/activated protein C receptor (EPCR) during mouse embryo development. Thrombosis & Haemostasis 2002; 88: 259-266.
44. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
45. Connolly AJ, Ishihara H, Kahn ML et al. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-519.
46. Ishiguro K, Kojima T, Kadomatsu K et al. Complete antithrombin deficiency in mice results in embryonic lethality. Journal of Clinical Investigation 2000; 106: 873-878.
47. Shworak NW, HajMohammadi S & Rosenberg RD. 3-OST-I deficient mice: normal haemostasis with unexpected perinatal phenotypes. Glycoconjugate Journal 2002;. (in press).
48. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
49. van der Meer FJ, Koster T, Vandenbroucke JP et al. The Leiden thrombophilia study (LETS). Thrombosis & Haemostasis 1997; 78: 631-635.
50. Cui J, Eitzman DT, Westrick RJ et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000; 96: 4222-4226.
51. Eitzman DT, Westrick RJ, Bi X et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002; 105: 2139-2142.
52. Broze Jr. GJ. Protein Z-dependent regulation of coagulation. Thrombosis & Haemostasis 2001; 86: 8-13.
53. Broze Jr. GJ. Protein-Z and thrombosis. Lancet 2001; 357: 900-901.
54. Vasse M, Guegan-Massardier E, Borg JY et al. Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet 2001; 357: 933-934.
55. Gris JC, Quere I, Dechaud H et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood 2002; 99: 2606-2608.
56. Yin ZF, Huang ZF, Cui J et al. Prothrombotic phenotype of protein Z deficiency. Proceedings of the National Academy of Sciences of the USA 2000; 97: 6734-6738.
57. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.
58. Ploplis VA, Carmeliet P, Vazirzadeh S et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-2593.
59. Even-Ram S, Uziely B, Cohen P et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Medicine 1998; 4: 909-914.